On average AstraZeneca, the vaccine has shown 70% efficacy in fighting against Covid19, as per the data published after almost 3 clinical trials conducted in the United Kingdom and Brazil.
The AstraZeneca vaccine which is developed by Oxford University results are that 70% of them who got vaccinated will not be infected by the virus.
When the experts tried two separate dosing methods, one of them showed nearly 90% of effectiveness.
In a statement issued it said, “Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing Covid-19, the primary endpoint, and no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine.”
The statement further said, “One dosing regimen (n=2,741) showed vaccine efficacy of 90% when AZD1222 was given as a half dose, followed by a full dose at least one month apart, and another dosing regimen (n=8,895) showed 62% efficacy when given as two full doses at least one month apart. The combined analysis from both dosing regimens (n=11,636) resulted in an average efficacy of 70%.”
In a further statement by Andrew Pollard, chief investigator, Oxford vaccine trial at oxford said that “These findings show that we have an effective vaccine that will save many lives. Excitingly, we’ve found that one of our dosing regimens maybe around 90% effective and if this dosing regime is used, more people could be vaccinated with planned vaccine supply.”
In the statement, the company said that it will, be carrying out a further investigation based on the data that gets produced over time, to improve the efficacy.
The company said, “The Company will seek an Emergency Use Listing from the World Health Organization for an accelerated pathway to vaccine availability in low-income countries. In parallel, the full analysis of the interim results is being submitted for publication in a peer-reviewed journal.”
Don’t have the time to read? Well, no problem. Listen to our amazing podcasts anywhere on the go. Click here.